Jennifer E. Workman

Preclinical Development Preclinical Characterization of OSI-027 , a Potent and Selective Inhibitor of mTORC 1 and mTORC 2 : Distinct from Rapamycin

P. Houghton, P. Gokhale, D. Epstein, 2011 .

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

P. Houghton, P. Gokhale, D. Epstein, 2011, Molecular Cancer Therapeutics.

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.

M. Albertella, P. Gokhale, D. Epstein, 2013, Bioorganic & medicinal chemistry letters.